Interview with Amy E. Cyr, MD, FACS: Personalization of Management for High-Risk Women

Interview with Amy E. Cyr, MD, FACS: Identification and Management for High-Risk Women

Interview with Ashley Frith, MD: Metastatic Disease Research Highlights from the 2025 San Antonio Breast Cancer Symposium

View all

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

Katie Newlin, Katie Newlin, RN, MSN, AGPCNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)

Abemaciclib Clinical Management Guide

Transgender Breast Cancer Screening

Clinical Characteristics and Treatment Persistence in US Patients with HR+/HER2-, Node Positive Early Breast Cancer Treated with Abemaciclib: Real-World Study from First Year After Approval

Ribociclib Plus Endocrine Therapy in Early Breast Cancer

Annals of Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: Final overall survival analysis of the phase 3 TROPION-Breast01 study

eLife

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

Biomedicines

Cryotherapy as a surgical de-escalation strategy in breast cancer: Techniques, complications, and oncological outcomes

Cancers

HER2-low and HER2-ultralow metastatic breast cancer and trastuzumab deruxtecan: Common clinical questions and answers

Breast Cancer Research and Treatment

Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression

The Breast

How should we manage abemaciclib in the peri-operative period during secondary breast reconstruction: Balancing oncologic benefit and surgical safety

Anti-Cancer Drugs

Efficacy and safety of fulvestrant combined with abemaciclib in patients with hormone receptor-positive advanced breast cancer

Anti-Cancer Research

Radiological complete response as a prognostic marker in HR-positive metastatic breast cancer treated with CDK4/6 inhibitors: Implications for treatment de-escalation

HR+ HER2- Breast Cancer Resource Center